PR Newswire recently released an article that was published on Markets Insiders on the recent collaboration between Pacira and Cancer Treatment Centers of AmericaThe article details the three goals of the Opioid Risk Reduction Initiative, the brainchild of Pacira Pharmaceuticals and Cancer Treatment Centers of America to raise awareness about opioid alternatives for pain management and the management of opioid use. The Chief of the Division of Anesthesia at the Cancer Treatment Centers of America, Neil Seeley, reveals that narcotics have been the center of pain management after surgery for cancer patients. If the patient remarked about the pain, oncology clinicians would prescribe more narcotics. This became problematic with the awareness of the risk of long term opioid use, revealing that it is not necessarily safe for post-surgical pain.

The Opioid Risk Initiative seeks to help both clinicians and patients by providing in-depth evidence-based material on opioid alternatives. They seek to educate the cancer patients about the different alternatives. However, when alternatives are not an option, they also seek to provide information about how to use opioids for responsible treatment. However, the Opioid Risk Initiative seeks to start a conversation in the medical community at large, seeking to stimulate awareness about responsible use of opioids and provide information on opioid alternatives. Likewise, they also seek to create a standard in hospitals to reduce opioid use for cancer patients completely.

Cancer Treatment Centers of America is a network of hospitals across the nation which realizes that no patient is exactly the same. They understand that each patient needs a personalized approach to their treatment. Their experts use the most cutting-edge technologies to manage side effects from cancer treatment. Cancer Treatment Centers of America provides precision medicine by taking the treatment to a cellular level. Doing so with genomic testing, immunotherapy and targeted therapy helps the oncologists to realize the molecular characteristics that let the tumor grow.